Article
Parathyroidectomy Does Not Reduce Mortality or Morbidity in Mild Primary Hyperparathyroidism
December 1, 2022
Dr. Morvant Clinical question: Does parathyroidectomy improve mortality or morbidity in mild primary hyperparathyroidism? Background: It is known that in patients with severe hypercalcemia or...
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
News
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
![1]()
News
Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
![1]()
News
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
![1]()
News
Opioid-induced adrenal insufficiency for the hospitalist
October 26, 2021
Opioid-induced adrenal insufficiency is an underrecognized cause of central adrenal insufficiency.
News
Some diabetes drugs may lower risk of severe COVID-19 outcomes
October 19, 2021
Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.
News
Age, C-reactive protein predict COVID-19 death in diabetes
September 29, 2021
“This means we can easily identify patients early on in their hospital stay who will likely require more aggressive interventions to try and improve survival.”
![1]()
News
Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs
September 27, 2021
SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.
![1]()
News
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
September 20, 2021
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say forget that.
